Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) launched and shipped its enhanced Leo System on Dec 9, 2025, an upgraded Simple Western platform combining chemiluminescence with dual-channel near-infrared and infrared fluorescence for expanded multiplexing.

Key capabilities include up to 24 targets per sample, support for multiplexing same-weight targets and proteoform pairs (e.g., phosphorylated vs total), resampling and RePlex workflows, processing up to 100 capillaries in three hours, and reported precision of 5–6% variability. The system also includes features to support 21 CFR Part 11 compliance.

Positive

• Dual-channel NIR/IR fluorescence plus chemiluminescence expands multiplexing
• Enables up to 24 targets per sample
• Processes up to 100 capillaries in three hours
• Reported precision of 5–6% variability
• Includes features supporting 21 CFR Part 11 compliance

Negative

• None.

Key Figures

Multiplexing capacity up to 24 targets per sample Enhanced Leo System protein analysis throughput

Capillary throughput up to 100 capillaries in three hours High-throughput Simple Western-based workflow

Assay variability 5–6% variability Precision achieved in clinical research setting using Leo

21 CFR Part 11 Part 11 compliance support Leo System supports 21 CFR Part 11 compliance needs

Price vs 52-week high -23.95% TECH price relative to 52-week high before launch news

52-week low $46.01 Lower bound of TECH’s 52-week trading range pre-announcement

Market cap $9,610,527,398 Equity value prior to Enhanced Leo System launch news

Short interest 3.29% of float Reported short position in shares before this news

Market Reality Check

$60.29 Last Close

Volume Volume 2,069,242 vs 20-day average 1,839,122 (relative volume 1.13x) ahead of the launch news. normal

Technical Shares at $60.29, trading above the $55.44 200-day moving average and 23.95% below the 52-week high.

Peers on Argus 1 Up

TECH was down 2.25% while close peers showed mixed, modest moves (e.g., JAZZ -0.58%, HALO -1.44%, BPMC +0.09%). Momentum scanner only flagged LEGN at +5.67% without news, pointing to stock-specific rather than sector-driven factors.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 25	Investor conferences	Neutral	+3.7%	Announcement of three early December investor conference presentations and webcasts.
Nov 18	AI licensing deal	Positive	-0.8%	Exclusive license to NovoBody Duo AI-designed bispecific binding proteins from Monod Bio.
Nov 06	Investor conferences	Neutral	-2.9%	Schedule of four November healthcare investor conference appearances with webcasts.
Nov 05	Earnings release	Neutral	-1.9%	Q1 FY2026 results with slightly lower sales but higher margins and Exosome divestiture.
Nov 04	AI clinical data	Positive	-0.3%	AI-powered spatial biology data in melanoma showing biomarker links to survival outcomes.

Pattern Detected

Recent news — including AI partnerships, clinical data, and earnings — often saw mildly negative or muted price reactions, even when operational updates appeared constructive.

Recent Company History

Over the last few months, Bio‑Techne has combined investor outreach, AI-driven innovation, and financial execution. Conference participation on Nov 6 and Nov 25, 2025 coincided with mixed reactions, while the Q1 FY2026 earnings release on Nov 5, 2025 showed stable adjusted EPS and improving margins yet was followed by a -1.9% move. AI-focused collaborations and spatial biology data updates also drew slightly negative or flat responses, suggesting the market has been cautious toward fundamentally positive developments.

Market Pulse Summary

This announcement highlights Bio‑Techne’s push to enhance its Simple Western-based Leo platform with dual-channel fluorescence, enabling up to 24 targets per sample and 100 capillaries in three hours at 5–6% variability while supporting 21 CFR Part 11 compliance. Set against recent AI collaborations and stable but pressured Q1 FY2026 sales, the news underscores a strategy centered on higher-throughput, regulated proteomic workflows. Key items to watch include product adoption trends and how management frames Leo’s impact in future filings and conference appearances.

Key Terms

chemiluminescence medical

"Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared..."

Chemiluminescence is light produced directly by a chemical reaction, similar to how a glow stick glows when its chemicals mix. In laboratory and medical testing it is used to make tiny amounts of a substance visible, so tests can detect disease markers or contaminants quickly and with high sensitivity. Investors care because chemiluminescent technologies power many diagnostic devices and assays, affecting product performance, regulatory approvals and potential revenue.

near-infrared medical

"dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges..."

Near-infrared is the band of light just beyond what the human eye can see, similar to a flashlight beam shifted slightly into a color you can’t perceive. It penetrates materials and tissue differently than visible light, so it’s widely used in medical imaging, sensors, remote sensing and quality-control tools; for investors, that means technologies using near-infrared can enable new products, regulatory pathways and revenue streams tied to diagnostics, monitoring and industrial inspection.

AI-generated analysis. Not financial advice.

• Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing
  
  
• Enables up to 24 targets per sample and supports complex assay configurations
  
  
• Strengthens Bio-Techne's leadership in proteomic analytical instruments and supports 21 CFR Part 11 compliance

MINNEAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the expanded launch and first shipment of its next-generation Leo™ System, powered by Simple Western™ Technology.

The enhanced Leo System introduces dual-channel fluorescence detection alongside chemiluminescence, expanding data throughput and efficiency, and generating greater insights from precious samples. Fluorescence adds a fourth multiplexing option to its molecular weight separation, RePlex, and resampling capabilities to create even more experimental flexibility and tackle complex biological questions. This advance enables researchers to simultaneously quantify targets with distinct expression levels, assess different proteoforms, such as phosphorylated and total protein forms, in the same capillary, multiplex same-weight targets in a single run, and process up to 100 capillaries within three hours.

"Leo represents the future of clinical research requiring absolute quantitation. We chose Leo for its high-throughput capabilities and are consistently achieving highly precise results with only 5–6% variability, which is truly remarkable," said Alexandre Lucas, Ph.D., Founder and Manager of We-Met, a research group at the French National Institute of Health and Medical Research (INSERM).

"The next-generation Leo System sets a new standard for our customers by delivering unmatched precision and efficiency in protein analysis," said Will Geist, President of the Protein Sciences Segment at Bio-Techne. "With advanced detection technologies and built-in compliance features, Leo enables researchers to achieve faster, more reliable results, accelerate critical discoveries, and streamline development timelines."

Explore Leo's enhanced functionality at bio-techne.com/leo and view its new fluorescence-based detection capabilities.

ABOUT BIO-TECHNE:

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the company on social media at LinkedIn, X, or YouTube.

MEDIA CONTACTS:

Corporate Communications
media.relations@bio-techne.com

David Clair, Vice President
Investor Relations & Corporate Development
investor.relations@bio-techne.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-launches-the-enhanced-leo-system-delivering-advanced-multiplexing-and-high-throughput-protein-analysis-302635690.html

SOURCE Bio-Techne Corporation

FAQ

What did Bio-Techne announce about the Leo System on December 9, 2025 (TECH)?

Bio-Techne announced the enhanced Leo System with dual-channel NIR/IR fluorescence plus chemiluminescence and first shipments on Dec 9, 2025.

How many targets per sample can the Leo System (TECH) quantify with the new update?

The enhanced Leo System supports multiplexing of up to 24 targets per sample.

What throughput does the Leo System (TECH) achieve after the upgrade?

The system can process up to 100 capillaries within three hours.

What precision did users report for Leo System (TECH) results?

A user reported achieving highly precise results with 5–6% variability.

Does the Leo System (TECH) support regulatory compliance for clinical research?

The Leo System includes built-in features to help support 21 CFR Part 11 compliance.